NFKBIZ expression is significantly downregulated in BC, and its low expression predicts a poor prognosis. (A) NFKBIZ expression in BLCA based on sample types in the Gene Expression Profiling Interacting Analysis database. (B) Expression levels of NFKBIZ based on RNAseq data in BLCA based on sample types in the Xena database. NFKBIZ expression according to (C) sample types, (D) different BC stages, (E) nodal metastasis status and (F) histological subtypes in the UALCAN database. (G) Reverse transcription-quantitative PCR analysis of NFKBIZ expression in 34 pairs of BC tissues and corresponding adjacent normal bladder tissues. *P<0.05; **P<0.01; ***P<0.001. (H) Representative western blot images and (I) quantitative analyses of NFKBIZ and β-actin protein expression in different cell lines. ***P<0.001 vs. SV-HUC-1. (J) Survival analysis was performed using the mRNA-reads count expression data from TCGA-BLCA dataset in patients with BC with high and low NFKBIZ expression. ns, not significant; BLCA/BC, bladder cancer; TCGA, The Cancer Genome Atlas; RNAseq, RNA sequencing; NFKBIZ, NF-κB inhibitor ζ.